Assistant
Ask
Navigate
Command

Profound Medical Corp. PRN.TO

Profound Medical Corp. is a commercial-stage medical device company that develops and commercializes incision-free therapeutic systems for image-guided ablation of diseased tissue. Its flagship TULSA-PRO system combines MRI, robotically-driven transurethral ultrasound, and real-time thermal feedback to ablate prostate tissue in a single outpatient session, while its Sonalleve system uses MRI-guided focused ultrasound to treat uterine fibroids and bone metastases.

Key ratios
FreeCashFlowOnSale TTM -2.38
FreeCashFlowOnSale 2025 -2.38
FreeCashFlowOnSale 2024 -2.2
FreeCashFlowOnSale 2023 -3.14
NetIncomeMargin TTM -2.64
NetIncomeMargin 2025 -2.64
NetIncomeMargin 2024 -2.6
ReturnOnAssets TTM -0.35
ReturnOnAssets 2025 -0.35
ReturnOnAssets 2024 -0.36
ReturnOnAssets 2023 -0.33
ReturnOnEquity TTM -0.67
ReturnOnEquity 2025 -0.67
ReturnOnEquity 2024 -0.61
ReturnOnEquity 2023 -0.68
Recent news
Robotic Radical Prostatectomy Comes Up 'Short' in CAPTAIN Trial 2026-07-24 · GlobeNewswire
Profound Medical Reports Strong First Quarter 2026 Financial Results 2026-05-07 · GlobeNewswire
An unhandled error has occurred. Reload 🗙